Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: In vitro and clinical studies

被引:69
作者
Greenblatt, DJ
von Moltke, LL
Perloff, ES
Luo, Y
Harmatz, JS
Zinny, MA
机构
[1] Tufts Univ, Sch Med, Dept Pharmacol & Expt Therapeut, Boston, MA 02111 USA
[2] Tufts Univ, New England Med Ctr, Boston, MA 02111 USA
[3] ProMedica Clin Res Ctr, Boston, MA USA
关键词
D O I
10.1016/j.clpt.2005.09.014
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives: Recent anecdotal, unvalidated case reports have suggested potentiation of warfarin-induced anticoagulation by cranberry juice, possibly through inhibition of human cytochrome P450 (CYP) 2C9, the enzyme responsible for the clearance of the active S-enantiomer of warfarin. To address this question, the effect of cranberry juice and other beverages on CYP2C9 activity was evaluated in vitro and in vivo. Methods: The effects of 4 beverages on CYP2C9 activity were studied in human liver microsomes, by use of flurbiprofen hydroxylation as the index reaction. In a clinical study 14 healthy volunteers received 100 mg flurbiprofen on 5 occasions in a crossover fashion, with at least 1 week separating the 5 trials. Flurbiprofen was preceded in random sequence by the following: (1) cranberry juice placebo (8 oz), (2) cranberry juice (8 oz), (3) brewed tea (8 oz), (4) grape juice (8 oz), and (5) fluconazole, a CYP2C9 inhibitor serving as a positive control, with 8 oz of water. Results: Flubiprofen hydroxylation in vitro was reduced to 11% +/- 8% of control by 2.5% (vol/vol) brewed tea, to 10% +/- 7% of control by grape juice, to 56% +/- 16% of control by cranberry juice, to 85% +/- 5% of control by cranberry juice placebo, and to 21% +/- 6% of control by the index inhibitor sulfaphenazole (2.5 mu mol/L) (P < .01 for all comparisons versus control). Flurbiprofen clearance (29-33 mL/min) and elimination half-life (3.3-3.4 hours) did not differ significantly among trials 1, 2, 3, and 4. However, clearance in the fluconazole treatment condition (trial 5) was significantly reduced compared with the placebo control (17 +/- 5 mL/min versus 31 +/- 8 mL/min, P < .05), and the half-life was prolonged (5.3 +/- 1.6 hours versus 3.3 +/- 0.8 hours, P < .05). Formation of 4-hydroxyflurbiprofen was correspondingly reduced by fluconazole (P < .05). Conclusions: Although grape juice and tea impaired CYP2C9 activity in vitro, none of the 3 beverages altered CYP2C9-mediated clearance of flurbiprofen in humans, making a pharmacokinetic interaction with warfarin highly unlikely.
引用
收藏
页码:125 / 133
页数:9
相关论文
共 60 条
[1]   Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications [J].
Aithal, GP ;
Day, CP ;
Kesteven, PJL ;
Daly, AK .
LANCET, 1999, 353 (9154) :717-719
[2]   Flavanone absorption after naringin, hesperidin, and citrus administration [J].
Ameer, B ;
Weintraub, RA ;
Johnson, JV ;
Yost, RA ;
Rouseff, RL .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 60 (01) :34-40
[3]   Drug interactions with grapefruit juice [J].
Ameer, B ;
Weintraub, RA .
CLINICAL PHARMACOKINETICS, 1997, 33 (02) :103-121
[4]   Grapefruit juice-drug interactions [J].
Bailey, DG ;
Malcolm, J ;
Arnold, O ;
Spence, JD .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 46 (02) :101-110
[5]   Biologically active secondary metabolites from Ginkgo biloba [J].
Bedir, E ;
Tatli, II ;
Khan, RA ;
Zhao, JP ;
Takamatsu, S ;
Walker, LA ;
Goldman, P ;
Khan, IA .
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 2002, 50 (11) :3150-3155
[6]   Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions [J].
Bertz, RJ ;
Granneman, GR .
CLINICAL PHARMACOKINETICS, 1997, 32 (03) :210-258
[7]   Allelic and functional variability of cytochrome P4502C9 [J].
Bhasker, CR ;
Miners, JO ;
Coulter, S ;
Birkett, DJ .
PHARMACOGENETICS, 1997, 7 (01) :51-58
[8]  
Black DJ, 1996, DRUG METAB DISPOS, V24, P422
[9]  
*COMM SAF MED MED, 2004, CURR PROBL PHARMACOV, V30, P10
[10]   CLINICAL PHARMACOKINETICS OF FLURBIPROFEN AND ITS ENANTIOMERS [J].
DAVIES, NM .
CLINICAL PHARMACOKINETICS, 1995, 28 (02) :100-114